Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNJ491)

Drug Name

IMGN529 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
Metastatic non-hodgkin's lymphoma	2B33.5	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukocyte antigen CD37 (CD37)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Otlertuzumab	DMAZIND	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[4]
BI-836826	DMWH7Z5	Diffuse large B-cell lymphoma	2A81	Phase 2	[5]
Naratuximab emtansine	DMSWUNX	Diffuse large B-cell lymphoma	2A81	Phase 2	[6]
TRU-016	DM9IQ4A	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[7]
GEN3009	DMD8RLY	B-cell non-hodgkin lymphoma	2B33.5	Phase 1/2	[8]
212Pb-labelled aCD37	DMLVADH	leukaemia	2A60-2B33	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01534715) IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
3	The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61.
6	Clinical pipeline report, company report or official report of Debiopharm.
7	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.
8	Clinical pipeline report, company report or official report of AbbVie.
9	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.